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Individual meals are products of a complex interaction of
signals related to both short-term and long-term avail-
ability of energy stores. In addition to maintaining the
metabolic demands of the individual in the short term,
levels of energy intake must also maintain and defend
body weight over longer periods. To accomplish this,
satiety pathways are regulated by a sophisticated network
of endocrine and neuroendocrine pathways. Higher brain
centers modulate meal size through descending inputs
to caudal brainstem regions responsible for the motor
pattern generators associated with ingestion. Gastric
and intestinal signals interact with central nervous system
pathways to terminate food intake. These inputs can be
modified as a function of internal metabolic signals,
external environmental influences, and learning to regu-
late meal size.
Introduction
While we often think that we make a conscious decision
regarding when to put down our fork, the reality is that inges-
tive behavior is orchestrated by a wide range of biological
signals that greatly impact how much we eat. Assuring suffi-
cient calories is vital to life and so it is not surprising that
evolution has selected for organisms with the ability to care-
fully regulate their food intake to match their energy needs.
Other than some ‘filter feeders’ that do not have to seek
out their food supply, most organisms organize their feeding
into discrete bouts that we call meals. Meal initiation is
largely opportunistic. Food availability, time of day and
learning all play important roles in determining when meals
begin. Determining when meals end, however, is largely a
product of biological signals that are generated by the phys-
ical, biochemical and signaling qualities of ingested food.
The purpose of this review is to detail what we know about
these so-called ‘satiety’ signals and how they are used to
make it possible for organisms to match their caloric intake
to their caloric needs and maintain a stable body weight.
Among these pathways are adaptations that enable us to
eat more than is necessary in the short term to guard against
uncertainty and scarcity over longer periods. Understanding
these processes has practical implications for the develop-
ment of weight-loss strategies.
Currently, the most effective treatment for obesity is
bariatric surgery [1]. Of the various options available Roux-
en-y gastric bypass is considered to be the gold standard
[2]. The surgery involves the formation of a small gastric
pouch directly beneath the esophagus. An area of space
that is roughly the volume of an egg prevents nutrients
from entering the greater stomach, and upper intestine.
The stomach empties through a surgical anastomosis with
the jejunum, vastly reducing the transit time of nutrientsMetabolic Diseases Institute, University of Cincinnati, 2170 E. Galbraith
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*E-mail: adam.chambers@uc.eduthrough the gastrointestinal tract and enhancing the release
of a number of intestinal satiety signals. It is unclear if, or to
what degree, gastric restriction or increases in intestinal
hormones are responsible for reductions in meal size after
this surgery. However, the weight loss produced by such
surgeries is much larger in magnitude and far more durable
than weight loss achieved by the traditional approaches of
diet and exercise [1]. The success of these surgeries points
to the important nature of the signals generated by the
gastrointestinal tract and has implications for the develop-
ment of less invasive weight-loss strategies.
Satiety
As anyone who has attempted to lose weight, and then
sustain that weight loss, can attest, overcoming the homeo-
static pathways that regulate meal size and frequency
through dieting alone is exceedingly difficult. Even the
most modest reductions in fat mass activate powerful meta-
bolic pathways that affect our motivation to eat and retain
calories. What makes weight loss so difficult is that these
physiological changes continue unabated until the lost
weight is regained. In the following subsections we discuss
the processes that give rise to the psychological states of
satiation (meal termination) and satiety (the subsequent
delay between meals). We explain how signals that originate
in the periphery are integrated in central nervous system
pathways to affect meal size, and how these pathways are
regulated by powerful endocrine changes in fat and other
tissues that affect feeding behavior over longer periods.
Gastric Distention
For most people, satiety is tantamount to the psychological
sensation of fullness. Gastric mechanoreceptors are acti-
vated by distention both during and after meals [3]. Maximal
distention occurs when inhibitory signals from the intestine
slow gastric emptying rates to asymptotic levels. It has
been postulated that meals end primarily, or even solely,
as a function of volume effects [4–6]. There is no question
that gastric volume is a rate-limiting factor in meal size. In
rats with an inflatable cuff surgically implanted around the
pylorus to prevent gastric emptying, infusing a gastric pre-
load reduces meal size in proportion to the volume of infu-
sate. Under these conditions, meal size is unaffected by
the caloric density of the preload [4]. Thus, in isolation the
stomach does not respond to differences in caloric density
or macronutrient composition crucial for normal sequences
of meal termination and the regulation of meal size. Rather,
caloric composition must be sensed post-gastrically.
Post-gastric Signals
Infusing nutrients into the intestine reduces meal size in pro-
portion to the number of calories infused [7]. Figures 1 and 2
show how cells located in the intestinal epithelium sense and
respond to nutrients. Under normal conditions, roughly a
third of all calories consumed exit the stomach prior to the
end of the meal [8–10]. What remains is gradually metered
out over time via negative feedback from the intestine.
Gastric emptying is thus characterized by an initial rapid
phase followed by a slower linear phase, in which emptying
rates are determined by caloric content rather than volume
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Figure 1. Nutrient-sensing in intestinal I-cells.
Luminal nutrients activate specialized recep-
tors coupled to Gq proteins at the surface
of enteroendocrine I-cells. The activation of
phospholipase C (PLC), and downstream
effector pathways triggers membrane depo-
larization and the release of cholecystokinin
(CCK: orange dots), which activates CCK1
receptors expressed on vagal afferent fibers.
Following uptake into epithelial cells, mono-
glycerides and free fatty acids can either
diffuse across the cell and exit into circulation
from the basolateral membrane, or be re-
synthesized into triglycerides (TG) by the
2-monoglyceride (2MG) or a-glycerol-3 phos-
phate (G3P) pathways. The re-synthesized
TGs are assembled into chylomicrons before
undergoing exocytosis by the Golgi appa-
ratus. Once in circulation, a portion of the
Apo A-IV dissociates from the chylomicron
and acts on CCK1 receptors via an unknown
mechanism (depicted by the question mark).
DAG, diacylglycerol; IP3, inositol (1,4,5)
trisphosphate; PK3, protein kinase 3.
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the regulation of the appearance of nutrients into the circula-
tion and in critical organs, such as the liver, is primarily a
function of gastric emptying.
As food exits the stomach, coordinated contractions of the
gallbladder release bile and pancreatic juices which, among
other things, contain high levels of bicarbonate. This neutral-
izes the acidity of the exiting chyme. In addition, these
secretions intersperse pancreatic amylase, trypsinogen,
and lipases that are necessary for digestion. Carbohydrates
and proteins are broken down into simple sugars and amino
acids, respectively, before being taken up by the intestinal
epithelium through active transport [12,13]. Lipids, however,
must be emulsified by bile before being cleaved into fatty
acids and monoglycerides by lipases and enter the entero-
cyte via passive diffusion, or active transport [14]. If nutrients
exit the stomach too quickly, malabsorption may occur. By
regulating the appearance of chyme into the intestine,
gastric emptying optimizes the digestion of these macronu-
trients within the proximal bowel.
For these processes to be effective, the gut must be able
to signal to multiple sites of action simultaneously — i.e.
the liver, gallbladder, pancreas, and stomach — in order to
coordinate these diverse responses required for efficient
digestion. Therefore, it is essential that the macronutrient
makeup and caloric intensity of the chyme be read with a
high degree of accuracy. Blood-borne factors are ideally
suited to this task in that they are able to reach multiple
tissues and organ systems simultaneously. Together with
the enteric nervous system, these signals control gastric
emptying in such a way that approximately the same amount
of calories per minute are emptied into the duodenum.
Intestinal Cholecystokinin
By the late 1960s and early 1970s improved extraction and
purification techniques made it possible to begin studying
the exogenous administration of relatively pure formulations
of peptide hormones in a much more pointed, and focused
way than in previous decades [15]. A landmark study
by Gibbs et al. [16] reported the effects of semi-purifiedcholecystokinin (CCK) derived from porcine intestine and a
synthetically derived form of CCK (CCK-8) on food intake in
rats. These authors found that meal size was significantly
reduced in rats after intraperitoneal administration of both
compounds.
Today, we know that CCK is released from specialized
intestinal cells called I-cells in the duodenum in response
to dietary nutrients, especially lipids and fatty acids
[17–19]. Figure 1 highlights how fatty acids and dietary amino
acids stimulate CCK release in the intestine. These nutrients
stimulate specialized G-protein-coupled receptors (GPR40/
GPR120) [17,19] located on the apical surface of I-cells and
the extracellular calcium-sensing receptor (CaSR) [18],
which responds to aromatic amino acids. When activated,
these receptors evoke CCK release into the portal circula-
tion, stimulating gall-bladder contractions and the release
of bile [20]. In addition to its effect on food intake, CCK has
direct and indirect inhibitory effects on gastric emptying,
including the relaxation of the proximal stomach, suppres-
sion of gastric and duodenal pressure waves, and contrac-
tion of the pylorus [21,22]. In each case, these effects are
mediated via the CCK1 receptor. The effect of CCK on food
intake is believed to be mediated through the vagus nerve,
as vagotomy prevents the anorectic effect of CCK in rodents
[23,24]. It has not been determinedwhether the effect of CCK
in humans is alsomediated entirely through the vagus: it may
well be that there is also an endocrine component to this
effect particularly in humans.
It is important to point out that, in order to be considered
as a satiety signal, a candidate hormone or peptide must
display features consistent with the physiological regulation
of energy intake that go beyond simply reducing food intake
[25]. It is generally agreed that a satiety factor should display
a short duration of action so as not to interfere with the
duration between meals. The signal should reduce food
intake at doses that reflect prandial levels, but not as a
consequence of visceral illness. Finally, blocking the endog-
enous signal should increase meal size relative to baseline
values. A broad range of evidence now demonstrates that
CCK fulfills each of these requirements [11,26–28].
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Figure 2. Nutrient-sensing in intestinal
L-cells.
The schematic shows G-protein coupled re-
ceptors and their effector pathways that
have been identified as potential nutrient sen-
sors on intestinal L-cells. Activation of these
receptors by specific nutrients in the lumen
triggers elevations in intracellular Ca2+ stores
and activation of the Ca2+-sensitive transient
receptor potential channel M5 (TRPM5)
[135,136]. The resulting depolarization trig-
gers the release of GLP-1 (red dots) and the
subsequent activation of GLP-1 receptors ex-
pressed on vagal afferent fibers. AC, adenylyl
cyclase; IP3, inositol (1,4,5) trisphosphate.
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Another satiety factor released in
response to lipids is apolipoprotein
A-IV (Apo A-IV). Apo A-IV is a 46 kDa
protein secreted from the small intes-
tine in response to lipid absorption
and chylomicron formation (Figure 1). Inside the enterocyte,
fatty acids are re-esterified and assembled along with
cholesterol and apolipoproteins into chylomicron particles.
Chylomicrons are composed of a triglyceride and choles-
terol core, coated with apolipoproteins, which serve three
main functions: to emulsify the lipid particles in the aqueous
environment of the lymph and blood; to maintain the struc-
tural integrity of the chylomicron particle; and to direct the
metabolism of the particles at the peripheral tissues by bind-
ing to cell-surface receptors or through enzymatic activities.
Once in the plasma, w25% of the chylomicron-associated
Apo A-IV diffuses from the chylomicron and can be found
in the lipoprotein-free fraction of the plasma as well as in
the high density lipoprotein (HDL) pool. Therefore, the pres-
ence of Apo A-IV in the periphery is uniquely linked to the
intestinal absorption and secretion of dietary lipid [25].
Circulating levels of Apo A-IV peak within 15 minutes of a
meal and remain elevated for approximately 30 additional
minutes [29]. Like CCK, Apo A-IV has inhibitory effects on
gastric emptying [30] and, when given peripherally, Apo
A-IV reduces food intake in rats in a dose-dependent manner
at doses that mimic prandial levels [31]. Also like CCK, Apo
A-IV is expressed in the hypothalamus, and central adminis-
tration of Apo A-IV reduces food intake [32].
Tso and colleagues recently reported that CCK-deficient
mice are unresponsive to the anorectic effect of peripherally
administered ApoA-IV [33], indicating that reductions in food
intake by Apo A-IV are mediated via a CCK-dependent
mechanism. These authors also found that the anorectic
effect of peripherally administered Apo A-IV was abolished
in rats after subdiaphragmatic vagotomy, and greatly atten-
uated in rats pretreated with the CCK1 receptor antagonist
lorglumide.
Intestinal Glucagon-like Peptide-1 (GLP-1)
While both CCK and Apo A-IV are preferentially released in
response to dietary fats, other gastrointestinal hormones,
such as the incretin hormone GLP-1, appear to be more
strongly regulated by carbohydrates. While not universal,
at least somework hasmade the case that GLP-1 is secreted
more strongly in the presence of glucose than isocaloric
amounts of fat [34]. GLP-1 is a 36 amino acid peptide derivedfrom the post-translational processing of preproglucagon,
which is made in intestinal L-cells. The number of GLP-1-
expressing cells increases distally along the gastrointestinal
tract [35]. The nutrient-sensing properties of intestinal L-cells
have yet to be fully elucidated (Figure 2), but at least part of
the secretory response of GLP-1 is mediated by the glucose
sensor/taste receptor T1R2–T1R3 and the G protein gustdu-
cin [36], which are expressed on the apical surface of GLP-
1-containing cells. Fats may be sensed directly or indirectly
through the stimulation of G-protein coupled receptor
(GPR) 120 by fatty acids [37,38] or the actions of bile acids
on TGR5 receptors [39,40]. In humans and rodents GLP-1
and GLP-1 analogues decrease food intake in a dose-
dependent manner [41,42] and inhibit gastric motility [43,44].
Since under normal feeding conditions GLP-1 is released
rapidly within minutes of a meal before most of the glucose
reaches the lower intestine, it seems likely that glucose acti-
vates the release of GLP-1 through means other than direct
contact with L-cells [45]. Consistent with this hypothesis,
Rocca and Brubaker demonstrated that the secretion of
GLP-1 from the ileum is regulated by a complex neuroendo-
crine loop, in which nutrients in the duodenum induce GLP-1
release from ileal L-cells via vagal innervation [46].
Once in the circulation GLP-1 undergoes rapid degrada-
tion by the enzyme dipeptidyl peptidase (DPP) IV. After pass-
ing through the liver, only 25% of the intestinally secreted
GLP-1 enters general circulation where the half-life is less
than 2 minutes [47,48]. It remains uncertain whether suffi-
cient amounts of intestinal GLP-1 reach post-hepatic sites.
Thus, the precise sites of action of intestinal GLP-1 are not
well defined. Subdiaphragmatic vagotomy substantially
reduces the satiating effect of intraperitonal infusion of
GLP-1 on spontaneous meals, but not the satiating of effect
of hepatic-portal vein infusions of GLP-1 in rats [49]. Taken
together, these data imply that it is likely that GLP-1 acts at
multiple sites of action to inhibit food intake. Like the other
satiety factors we have discussed so far, GLP-1 also confers
inhibitory effects on gastric emptying mediated via the
vagus [50].
While GLP-1 is regarded as a putative satiation factor
there are two aspects of GLP-1 signaling that deviate from
the criteria initially put forth by Gibbs and Smith. First, of
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Figure 3. Integration of satiety signals by the
central nervous system.
Examples of peripherally derived signals that
act on central nervous system pathways to
affect food intake. Nutrient sensing is distrib-
uted across multiple regions of the central
nervous system. Circuits in the hypothalamus
(Hypo) and brainstem interact with higher
centers to initiate and terminate meals. ARC,
arcuate nucleus; NA, nucleus accumbens;
NTS, nucleus of the solitary tract; PFC,prefron-
tal cortex; VTA, ventral tegmental area; GLUT2,
glucose transporter 2; IR, insulin receptor.
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antagonists to increase meal size [51,52], only one found
that it did so [52], and in that study this effect was only
observed at times when food intake was otherwise low.
The rather limited conditions of this effect imply that further
work is needed beforemeaningful conclusions can be drawn
regarding the role of endogenously released GLP-1 on meal
size. Second, there is evidence that the pharmacological
activation of the GLP-1 system increases the duration of
satiety. Peripheral or intracerebroventricular chronic treat-
ment with long-acting pharmacological GLP-1 analogues,
such as exendin-4 and liraglutide, increase intermeal inter-
vals [52] and produce significant weight loss in rodents [41]
and humans [53]. It should also be noted, however, that
these compounds are designed specifically to have much
longer half-lives than the native peptide [54]. Consequently,
it is difficult to know whether such effects are reflective of
the endogenous biological actions of GLP-1 or are a product
of pharmacological activation of GLP-1 receptors for longer
periods and in more distal locations than would occur for
endogenous GLP-1 that is secreted after meals [3].
Peptide YY (PYY)
Peptide YY (PYY) is a 36 amino acid peptide that belongs to
the pancreatic polypeptide family that is co-secreted from
L-cells with GLP-1. Two endogenous forms of PYY are re-
leased into the circulation — PYY1-36 and PYY3-36. Additional
PYY3-36 is created by cleavage of the Tyr–Pro amino acid res-
idues of PYY1-36 by the enzyme DPP-IV, the same enzyme
responsible for the degradation of GLP-1. Under fasting con-
ditions, circulating levels of PYY1-36 are much higher thanlevels of PYY3-36. After ameal, however,
this relationship is reversedandPYY3-36
becomes the dominant form of the
peptide in the bloodstream [55].
The secretion of PYY3-36 may be
regulated by the same nutrient-sensing
receptors and pathways as GLP-1.
Unlike GLP-1, however, PYY is prefer-
entially secreted in response to fat
[56] and has no incretin effect, i.e. its
release does not potentiate glucose-
stimulated insulin secretion [57]. Like
GLP-1, PYY inhibits gastric emptying
and reduces intestinal transit times,
actions that help to lower prandial
glucose excursions and facilitate the
digestion of fats and other nutrients in
the proximal bowel.The mechanism and routes through which PYY exerts its
anorectic effects are distributed across multiple regions of
the central nervous system. Baraboi et al. [58] showed that
PYY3-36 reduces food intake both through hormonal actions
on circumventricular organs and direct effects on Y2 recep-
tors on vagal afferent fibers. In addition, there is evidence
that PYY crosses the blood–brain barrier where it may exert
actions on Y2 receptors expressed on neuropeptide Y (NPY)
neurons in the hypothalamus, preventing inhibitory feedback
onto pro-opiomelanocortin (POMC) neurons (Figure 3) [59].
Functional magnetic resonance imaging studies have shown
that, in addition to affecting hypothalamic and brainstem
regions, PYY3-36 alters activity in midbrain regions in the
mesoaccumbens area associated with reward [60]. Hence,
PYY3-36 is thought to affect multiple aspects of food intake
to exert its anorectic effect.
Amylin
Amylin is a 37-residue peptide from the calcitonin protein
and is co-secreted with insulin from b-cells in the pancreas
[61]. In rats, amylin is secreted into the circulation within
minutes of a meal where it has a half-life of approximately
15 minutes [62]. Peripherally administered amylin reduces
meal size at doses that match prandial circulating levels
without producing signs of visceral illness [63–65]. Further,
antagonists of the amylin receptor increase meal size at
doses that block the actions of exogenously administered
amylin [66,67]. For these reasons, it is widely held that amylin
fulfills the criteria of a physiological signal of satiation. Like
CCK and the other satiety factors described so far, amylin
has inhibitory effects on gastric emptying that are vagally
Special Issue
R383mediated [68]. Unlike CCK, the effect of amylin on food intake
results from actions in the area postrema, a circumventricu-
lar organ that lacks a normal blood–brain barrier as a result of
high concentrations of fenestrated capillaries. In rodents,
electrolytic lesions to the area postrema prevent amylin-
induced reductions in food intake [69,70].
Special Considerations of Knockout Models
Despite the above pharmacological evidence, amylin
knockout mice have normal food intake and growth curves
compared with wild-type mice [71,72]. However, it must be
recognized that genetically modified mice are subject to
developmental compensation that limit the interpretations
of negative data as a true absence of a function. Apo A-IV
[73] andGLP-1 receptor [74] knockoutmice also eat normally
and have normal growth patterns relative to wild-type mice.
CCK receptor deficient rats eat largermeals thanwild-type
rats [75]. However, CCK is also expressed in the hypothala-
mus where it negatively regulates the expression of NPY.
Thus, it is not clear whether the CCK deficiency affects
meal size through central or peripheral sites of action. The
same can be said of many of the metabolic cells in the
gastrointestinal tract, as most such peptides and transmit-
ters are also expressed in the central nervous system in
areas of the brain that regulate food intake. The key point
is that physiological conclusions from animals with targeted
gene disruption of these factors must be made with caution.
Integration of Signals by the Central Nervous System
The previous section described only several of a number of
satiety factors that are produced in the gut. When consid-
ered as a whole, the number and breadth of these signals
is impressive. These signals converge at multiple levels of
the central nervous system. This convergence occurs as a
function of both integrated signaling systems within indi-
vidual neurons and communication between sets of neurons
that receive separate peripheral inputs. Signals from the
periphery act at vagal afferent fibers that connect to higher
centers via the brainstem, or enter the brain from the circula-
tion through active transport, or passive transport at circum-
ventricular organs, such as the area postrema (Figure 3).
Vagal Afferent Signaling
At the cellular level, CCK is one of a number of inputs onto
vagal afferent fibers innervating the viscera and gastrointes-
tinal tract. Rather than responding to a single modality, or
peptide, vagal afferent fibers integrate signals from multiple
sources. For example, many neurons in the nodose ganglion
bearing CCK1 receptors also express the Ob-Rb receptor for
the anorectic hormone leptin and respond to mechanically
induced distention of the stomach [76]. These inputs can
be simultaneously affected by other gastric and intestinally
derived factors to regulate overall neuronal activity [77].
Hence, it is the balance of these inputs that is considered
to be important in determining meal size.
In many cases, the convergence of these signals is often
complex, and counterintuitive. For example, rather than
being secreted from adipose tissue, the leptin that acts
upon vagal afferent fibers is secreted from the gastric
mucosa, before traveling to the duodenum where it gains
access to vagal afferent fibers expressing CCK receptors
[78]. The reason for this is unclear. What is known is that
gastric leptin is secreted with its soluble receptor in a com-
plex that protects it from the hydrolytic conditions of thestomach [79]. This complex then moves to the duodenum,
where it interacts with transmembrane leptin receptors
expressed on the apical surface of CCK expressing I-cells
[80]. Once inside the cell, leptin is transferred to the Golgi
apparatus where it forms a new leptin–leptin receptor
complex before being secreted into lymph [81]. In addition
to CCK, leptin potentiates neuronal activity caused by
gastric distention, demonstrating that different pro-
cesses contribute additively to the overall activity in these
neurons [76].
Importantly, these inputs can also be opposed by other
factors, such as ghrelin, levels of which peak just prior to a
meal and fall precipitously soon afterwards. Pharmacologi-
cally, ghrelin increases food intake and palatable ratings
for food in humans and increases food intake and adiposity
in rodents [82,83]. Ghrelin is a 28 amino acid peptide
released from the oxyntic cells of the gastric mucosa [84].
The active form of ghrelin is produced when preproghrelin
undergoes a post-translational modification by the enzyme
ghrelin O-acyltransferase (GOAT), resulting in the esterfi-
cation of a medium-chain fatty acid to a serine 3 residue
that is necessary for binding to and activating the growth
hormone secretagogue receptor (GHSR) [85]. Circulating
levels of ghrelin are inversely related to fat mass [86] and
are regulated in the short term by the time of day [87],
duration of intermeal interval, and anticipatory meal-related
cues [88]. In addition to increasing food intake, ghrelin
opposes the actions of CCK and leptin on vagal afferent
fibers directly and by inhibiting activity caused by mechan-
ical distention [89].
The convergence of multiple inputs onto the same
afferent neuron allows the vagus to integrate large volumes
of information. As a consequence, these neurons are able to
respond rapidly to changes in the internal milieu brought
about by feeding. Moreover, the release of multiple signals
in response to a single stimulus results in greater sensitivity
and detection thresholds. For example, the presence of
lipids in the intestine results in the release of multiple satiety
factors, including CCK, Apo A-IV, GLP-1 and others, that in
turn lead to a high degree of accuracy in nutrient-sensing
networks spread throughout the periphery and central
nervous system pathways. This organization protects the
organism from relying too heavily on any one input since it
is the activity of these areas as a whole that is important
to overall response. Thus, the removal of any one peptide
or signal in isolation, either pharmacologically or through
targeted deletion, produces only modest effects on meal
size, a fact that is all too apparent in many pharmacologi-
cally based weight-loss strategies that generally result in
weight loss of only 5% or less compared with placebo-
treated individuals [90]. While even small amounts of weight
loss can lead to metabolic improvements [91], this <5% loss
falls well short of helping individuals reach an ideal body
weight.
One reason for the success of bariatric approaches to
obesity may be related to its actions on multiple pathways
in the periphery. Roux-en-y gastric bypass profoundly in-
creases prandial CCK [92], Apo A-IV [93], GLP-1 [92,94,95],
PYY [92,95], amylin [96], insulin [94,95], glucagon [92] and
other factors as part of an integrated response to surgically
induced changes in nutrient handling. These changes may
incur and maintain weight loss independent of the gastric
restriction that is also produced by this surgery. Total weight
loss after Roux-en-y gastric bypass can be in excess of
Current Biology Vol 23 No 9
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pathways may be one way to overcome the 5% ceiling effect
seen in traditional weight-loss approaches.
The Brainstem
In addition to relying on multiple signals, nutrient sensing is
distributed across multiple regions of the central nervous
system. Most of the vagal afferent fibers that innervate the
viscera and gastrointestinal tract project to the nucleus of
the solitary tract of the brainstem in the region rostral to
obex (Figure 3) [97]. Within this region, a vast number of
neuronal phenotypes are responsive to meal-related stimuli,
including adrenergic neurons that project to the paraventric-
ular nucleus of the hypothalamus [98], and GLP-1-express-
ing cells that project to the paraventricular nucleus, dorsal
medial hypothalamus [99], and ventral tegmental area [100].
In the nucleus of the solitary tract, neurons respond to
changes in circulating glucose [101] and the amino acid
leucine [102], demonstrating direct sensitivity of this region
to ambient levels of energy-yielding substrates. It remains
to be established whether ascending projections to the fore-
brain are necessary for nutrient-sensing pathways in the
brainstem to effect changes in meal size or frequency.
At one time, nutrients were thought to be sensed exclu-
sively in the gut and specific regions of the hypothalamus
[103]. Today, we know that this nutrient-sensing network is
also distributed in the brainstem. Likewise, we now know
that many neurons in the hypothalamus [104,105] also sense
and respond to the secretion of satiety factors that at one
time were thought to act exclusively upon metabolic path-
ways in the brainstem. Early lesioning studies also implied
that the brainstem lacked direct access to long-term meta-
bolic signals, such as leptin [106].
More recent evidence, however, demonstrates that a sub-
poplulation of neurons in the nucleus of the solitary tract
expresses the long form of the leptin receptor (ObRb)
[107]. These neurons project to the ventral tegmental area
and lateral hypothalamic areas and may affect food intake
through actions on dopamine signaling in motivation and
reward-related areas. Targeted disruption of ObRb signaling
exclusively in neurons in the nucleus of the solitary tract re-
sults in increased food intake and early-onset obesity in
mice [107], albeit to a lesser degree than that produced in
whole-animal leptin receptor disruption. The key point is
that metabolic pathways in the brainstem integrate and
respond to acute and long-term changes in energy homeo-
stasis as part of a broader network.
Today, the hypothalamus continues to be recognized for
its role in the integration ofmetabolically relevant information
from the hindbrain and elsewhere. The difference is in our
awareness of how the same information is processed simul-
taneously in other areas before being integrated in the
hypothalamus and other centers. As stated earlier, this distri-
bution protects the organism from relying too heavily on any
one input and increases the sensitivity with which it is able to
detect and respond to change.
The Hypothalamus
Among themostprominent centers for the integrationof such
signals is the basomedial region of the hypothalamus. Orexi-
genic NPY and anorectic POMC neurons respond to acute
and long-term metabolic inputs in opposing ways. POMC-
expressing neurons cleave POMC into a-melanocyte-stimu-
lating hormone (a-MSH), which acts upon melanocortin-3and melanocortin-4 receptors (MC3 and MC4) located in
the paraventricular nucleus and elsewhere [104,108]. Activity
at these receptors elicits powerful reductions in food
intake and increased energy expenditure [109–111]. NPY-
expressing neurons in arcuate anddorsomedial hypothalam-
ic nuclei project to the paraventricular, ventral medial, and
lateral hypothalamic areas. The release of NPY from these
neurons increases food intake through actions at Y1, Y2
and Y5 receptor subtypes [112].
Activity in both NPY and POMC neurons is regulated by
changes in circulating leptin secreted from adipose tissue.
In NPY-expressing neurons, decreases in leptin reduce inhi-
bition of a slow depolarizing current [113], resulting in greater
NPY release and larger meal sizes, whereas reduced leptin
signaling in POMC neurons results in the opposite effect.
These compensatory increases in food intake result in the
restoration of weight loss and defend body energy stores.
To regulate meal size, both NPY and POMC neurons send
dense projections to the paraventricular nucleus [114], which
in turn projects to adrenergic neurons in the nucleus of the
solitary tract that regulate meal size [115–118]. By putting
on weight, consequent increases in leptin increase the
output from POMC neurons that ultimately render an individ-
ual more sensitive to the anorectic effect of CCK and other
satiety factors [15]. Increased leptin action on NPY neurons
produces the opposite effect. In this way, adiposity signals
establish thresholds for the actions of satiety factors by
modulating the sensitivity of the nucleus of the solitary tract
to signals that terminate meals. Hence, it is the balance of
NPY-induced anabolic responses and a-MSH-induced
catabolic responses that is considered to be important.
Like pathways in the brainstem, neurons in the basomedial
hypothalamus also respond to acute changes in nutrient flux,
including circulating levels of all three macronutrients
[119–122], numerous satiety signals [104], and other factors
[123]. For example, circulating ghrelin stimulates activity
in NPY neurons in the arcuate nucleus [104], and ghrelin-
induced increases in food intake are prevented by NPY
receptor antagonists [124,125]. CCK, GLP-1, PYY and other
signals of acute changes in energy balance produce similar
effects, either through the circulation or through ascending
inputs from the brainstem. These inputs influence our deci-
sions about when and how much to eat that are, in part,
reflected by activity in motivation and reward-related
pathways and in areas of the brain involved in executive
decision making, such as the prefrontal cortex.
Reward Pathways
Among the regions affected by various metabolic inputs
are the dopaminergic pathways of the mesoaccumbens
pathway. Palatable foods, sexual activity, or drugs of abuse
all result in an increase in dopamine release from neurons in
the ventral tegmental area and the adjacent substantia nigra
into forebrain structures, such as the nucleus accumbens
[126–128]. Activity in these regions increases when we antic-
ipate having access to palatable foods [129] as well as when
we consume them [129,130]. Neuroimaging studies per-
formed in humans demonstrate that, generally speaking,
the hungrier one is, the greater the activity in the prefrontal
cortex [129,130]. These examples link endocrine activity
with motivational and reward-related processes in the fore-
brain and provide a neural correlate for what most of us
already know through experience, which is that the hungrier
you are, the more attractive food can be.
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factors affect these regions are becoming clearer. Leptin can
affect dopamine release in the nucleus accumbens by
engaging pathways in the nucleus of the solitary tract and
lateral hypothalamus [131], or through actions on ObRb
receptors expressed in the ventral tegmental area directly
[132]. Leptin-induced activity in these cells restores dopa-
mine content in leptin-deficient animals and is associated
with decreased food intake and weight loss in rats [131].
Likewise, long-term RNAi-mediated knockdown of ObRb in
the ventral tegmental area leads to increased food intake
andweight gain in rodents. The presumption is that, by inhib-
iting dopaminergic neurons in these pathways, leptin
reduces the reward incentive for food.
GLP-1-producing cells in the nucleus of the solitary tract
project directly to the ventral tegmental area and the nucleus
accumbens, and pharmacological data show that GLP-1
receptor activation in these areas decreases food intake,
especially of highly palatable foods [133]. Antagonism at
GLP-1 receptors in the ventral tegmental area significantly
increases food intake, establishing the physiological rele-
vance of centrally derived GLP-1 signaling in this region
and the influence of ascending pathways in the brainstem
on reward-related processes in higher centers [133].
As in other areas of the brain, the actions of leptin and
GLP-1 in the ventral tegmental area are opposed by the
orexigenic hormone ghrelin and the GHSR receptor. Ghrelin
administered directly into the ventral tegmental area simu-
lates accumbal dopamine release [134], m-opioid receptor
expression in the ventral tegmental area, and the consump-
tion of sweetened beverages in rats [125]. Ghrelin adminis-
tered intravenously to healthy volunteers during functional
magnetic resonance imaging increases the neural response
to food pictures in the orbitofrontal cortex and striatum and
increases subjective ratings for palatable foods.
Concluding Remarks
Over short periods of time, constraints on meal size reflect
the capacity of the gastrointestinal tract and viscera to
cope with increases in nutrient flux. This information is pro-
vided in the form of satiety factors that reflect the macronu-
trient and caloric characteristics of the chyme. As gastric
emptying slows, distention-related signals from the stomach
act upon neuronal networks in the brainstem that combine
with CCK and other satiety signals to terminate food intake.
The thresholds for meal termination can be modulated
through descending projections to the brainstem and
viscera. Inhibitory projections from the paraventricular
nucleus attenuate meal-induced activity in the nucleus of
the solitary tract, while descending inputs from the dorsal
motor nucleus mobilize insulin and other factors through
innervation to the pancreas, liver and gall bladder to accom-
modate greater increases in nutrient flux to alter meal size
when necessary. These networks are regulated by internal
and external cues that converge at multiple levels of the
peripheral and central nervous systems to affect food-
related behaviors, such as the initiation and termination of
meals. Activity in these networks is regulated by multiple
and redundant inputs, limiting the influence of any one signal
in isolation on these behaviors.
Eating remains a critical biological function and its com-
plex regulation reflects its importance to the survival of the
organism. Our increasing knowledge of how this system is
organized opens up new possibilities to understand whywe gain weight in our modern environment. Maybe more
importantly, our growing knowledge of these systemsmakes
it possible to make this biology work for us in the service of
new therapies that can reduce food intake and body weight.
The success of bariatric surgical procedures points to the
ability of altered signals to achieve substantial and sustained
weight loss. Harnessing those signals without the need for
surgical rearrangement of the gastrointestinal tract remains
an elusive but important research goal.
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